Moreover, results of a clinical trial carried out in northern Italy on COVID‐19 patients with psoriasis and treated with IL‐17A inhibitors showed a relatively low hospitalization rate (four out of 5206), suggesting a protective role of IL‐17A inhibitors against COVID‐induced cytokine storm. This evidence concerns the gene IL17A and psoriasis.